ArticleEye (London, England)2026
OCT predictors discerning progression to neovascular vs atrophic age-related macular degeneration.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo characterise structural optical coherence tomography (OCT) biomarkers at intermediate age-related macular degeneration(iAMD) stage able to differentiate the progression to neovascular AMD(nAMD) or to geographic atrophy (GA) in a high-risk iAMD population showing conversion at 1-year follow-up.
methodsmulticentre, retrospective, longitudinal study including patients with iAMD at baseline who developed late AMD (nAMD or GA) during the 1-year follow-up. Patients were enroled in three retinal referral institutions: (1) San Raffaele University, Milan, Italy; (2) IRCCS Bietti Foundation, Rome, Italy; (3) University of Paris Est, Creteil, France. Logistic regression model (LRM) analyses were performed to evaluate the prognostic ability of the studied biomarkers in discriminating between nAMD and GA conversion.
resultsWe included 154 eyes (154 patients, mean age 80 ± 7 years old) with iAMD at the baseline. Eighty-eight eyes(57%) progressed to nAMD, whereas 66 eyes(43%) progressed to GA. Eyes that progressed to nAMD were characterised by a higher double-layer sign(DLS) prevalence (p < 0.001), whereas eyes that progressed to GA were characterised by greater height and diameter of the greatest drusen (p < 0.001 and p = 0.001, respectively), higher presence of HRF(p = 0.008), and iRORA(p < 0.001). LRM confirmed that DLS is a significant risk factor for nAMD conversion (OR:3.626, p = 0.037), whereas height of greatest drusen (OR:0.983, p = 0.003), presence of HRF (OR:0.147, p = 0.009), and presence of iRORA (OR:0.052, p < 0.001) were more associated with GA conversion.
conclusionsStructural OCT biomarkers at the iAMD stage could help clinicians to distinguish between patients who will develop nAMD in comparison to GA. Our findings can contribute to the better management of patients with iAMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.